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To the Editor:
Currently, the world is witnessing a health crisis in the form
of COVID-19 pandemic [1]. For oncologists, especially for
stem cell transplant specialists, the stress is high to perform
to their best of capability for their cancer patients. In gen-
eral, the hematopoietic stem cell transplantation (HSCT) is a
high-risk procedure. The novelty of the COVID-19 disease,
lack of literature, absence of antiviral agent, and vaccine has
added more uncertainty while preparing for and recovering
from HSCT.
Accomplishing an HSCT is the result of a collaborative
effort including the transplant team working closely with
the referring physicians, and for the case of unrelated
allogeneic transplants, there needs to be a good commu-
nication and co-ordination between the transplant center
and donor center teams. In addition to this, the well-being
of transplant recipients and donors is mandatory for the
procedure. In the current situation, with the COVID-19
pandemic unraveling around the globe, the transplant
specialists ought to anticipate a complex path ahead with
unexpected challenges. Accomplishing HSCT becomes
more complex in cases of matched unrelated donor
transplantation due to the additional logistic issues of
transportation of the harvested stem cells.
In transplant programs across the globe, physicians are
trying to prevent COVID-19 infection in transplant recipients
and their respective donors so that HSCT could be conducted
smoothly and risk-free. Both EBMT and ASTCT’s special
subgroups, transplant infectious disease-special interest group,
have issued interim guidelines for recipients, and donors
of HSCT (https://mdedge.com/hematology-oncology/article/
219068/transplant/covid-19-astct-issues-interim-guidelines?
channel=63993, https://ebmt.org/sites/default/files/2020-03/
EBMT%20COVID19%20guidelines%20v.4.3%20%282020-
03-23%29.pdf). EBMT has recently updated their recom-
mendations (version 4.3 dated 23 March, 2020) and we have
summarized the same as below.
(A) Recommendations for Transplant candidate patient
(HSCT and cellular therapy recipients)
(Adapted from EBMT, version 4.3 dated 23 March,
2020)
● All recipients should have COVID-19 RT-PCR tested
negative before starting conditioning regimen irrespec-
tive of respiratory symptoms.
● All recipients who are supposed to be admitted for
HSCT/cellular therapy are advised for home isolation
for 14 days before starting the transplant conditioning.
Also, to avoid the non-necessary clinic visits to reduce
the risk to a minimum. This is now very well helped by
the sudden emergence and ability to use telemedicine
visits in place of in-person visits, especially in the
United States.
● If a recipient has a close contact with COVID-19
confirmed case:
All transplant-related procedures (PBSC mobiliza-
tion, BM harvesting, and conditioning) should not be
performed within at least 14 days and preferably 21 days
from the last date of contact
AND
The recipient should be closely monitored for
COVID-19 symptoms
AND
COVID-19 RT-PCR negativity is confirmed before
any transplant procedure is undertaken.
● If a recipient gets a COVID-19 disease, European Centre
for Disease Prevention and Control recommends
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deferral based on the risk of dying due to cancer in the
absence of HSCT/cellular therapy.
High-risk cancer disease: Deferral until the recipient
COVID-19 patient is asymptomatic and has two
repeated virus PCR negativity at least 1 week apart
(deferral of 14 days minimum).
Low-risk cancer disease: Deferral for 3 months.
(B) Recommendations for donor
(World Marrow Donor Association (WMDA) issued the
recommendations and the EBMT has endorsed these
guidelines version 4.3 dated 23 March, 2020)
● If a donor gets a COVID-19 disease, he/she must be
excluded from from stem cell donation. As of now, there
are no recommendations as when COVID-19 positive
donor can be cleared for donation but at least 3 months
deferral can be considered unless the need for donation
is urgent when individual consideration should be made.
● If a donor gets a close contact with a COVID-19
confirmed case, the decision depends on the urgency of
transplant: [A] In the case of nonurgent transplant: Stem
cell harvest shall be deferred for at least 28 days AND
donor should be watched closely for any symptoms.
[B] Urgent need of transplant: If the donor is completely
well, AND a COVID-19 test is negative AND there are
no suitable alternative donors, an earlier collection may
be considered subject to careful risk assessment if local
quarantine requirements permit.
● If a donor has traveled to high-risk areas for COVID-19
(as defined by health authorities) or came to close
contact with an individual traveling from such an area,
the donor should be excluded from donation for at least
28 days.
● A donor is expected to follow all the health hygiene and
precautions such as avoiding crowded places and large
group gatherings (as per WHO recommendations)
within 28 days before the donation date.
(C) Recommendations for post HSCT and post CAR-T
cell recipients
(Adapted from EBMT, Version 4.3 dated 23 March,
2020)
● To follow all the necessary precautions such as hand
washing and social distancing in order to restrict
the exposure to infected individuals.
● To refrain from unnecessary travel and in case required,
to travel by private car rather than using public
transportation.
● To test for COVID-19 with diagnostic procedures as per
national guidelines. Recipients belonging to high-risk
transmission area of SARS-CoV-2 virus infection or
having a close contact to a person to such areas should
be tested. COVID-19 testing can be repeated if there is
strong clinical suspicion for COVID-19 due to the
chance of false-negative results. Multiplex PCR is
recommended that allows testing for non-SARS-CoV-
2 viral infections as well.
● If detected positive for COVID-19, the recipient should
be evaluated with imaging study preferably CT chest
and for the need of oxygen requirement.
● Bronchoalveolar lavage (BAL) is not routinely recom-
mended due to the risk of airborne transmission to health
care workers. Only if other coinfections are suspected
and in cases with mechanical ventilation, bronchoscopy
should be performed and BAL samples should be tested
for COVID-19 and other co-pathogens.
Guidelines are generated based on evidences, but
unfortunately till now there is a lack of enough clinical
experience on COVID-19 in HSCT setting to pave formal
guidelines. The currently available recommendations issued
from the transplant societies of the United States (ASTCT)
and Europe (EBMT) are interim and additional guidance is
expected to be following in the next few weeks.
Recognizing the paramount importance of data gather-
ing, international donor registries like WMDA, and Center
for International Blood and Marrow Transplant Research
(CIBMTR) have made necessary changes in their data
collection forms in order to capture all the details of the
impact of the COVID-19 pandemic on the transplant and
cellular therapy recipients (https://share.wmda.info/display/
DMSR/Coronavirus+-+COVID-19#/, https://cibmtr.org/
ReferenceCenter/Covid19/Pages/default.aspx#comm).
CIBMTR has modified Transplant Essential Data track and
Comprehensive Report Form track reporting to include a
new organism option COVID-19 (SARS-CoV-2) that will
entail more detailed data collection (https://cibmtr.org/Data
Management/Communications/TrainingNewsletters/
Documents/Collecting_Data_on_the_Impact_of_the_
COVID_19_on_our_Recipients_015.pdf).
Dr Ljungman (EBMT) recently shared their data from
Europe on post HSCT COVID-19 cases. As of March 20,
2020, 15 cases of COVID-19 cases in post-HSCT setting
(15 allogenic and 3 autologous) have been reported from
Europe. Most cases were reported from Spain (five patients)
followed by Italy (three patients). The median age of the
patients was 59 years, ten patients presented with upper
respiratory symptoms and remaining with lower respiratory
tract systems. Out of these, one patient has already suc-
cumbed to COVID-19 illness (https://ebmt.org/covid-19-a
nd-bmt).
Despite practicing all the correct steps and following
recommendations, last-minute hurdles can overturn all the
strategies for which a transplant team should be ready to
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tackle the unpredicted situations. Few of them could be (1)
donor getting infected between clearance for donation and
the actual date of the cell apheresis, or (2) harvest center
staff falling sick to COVID-19 disease on the day of har-
vest, or (3) difficulties to transport harvested stem cells
across the border due to travel restrictions. Similarly,
the ASTCT has endorsed the “Practical Guidance for
the BMT Centers” suggested by the Adult BMT Service
team at Memorial Sloan Kettering Cancer Center [MSKCC,
v1.0 March 25, 2020] (https://astct.org/viewdocument/
guidance-for-bmt-centerfunctioning?CommunityKey=
d3949d84-3440-45f4-814290ea05adb0e5&tab=libra
rydocuments). The MSKCC BMT guide also recommends
cryopreservation of all related and unrelated donor products
just like WMDA and EBMT. They also recommended
considering peripheral stem cell collection over marrow
collection, to prefer domestic donors/cord blood banks over
international ones, and to have a backup donor preferably
for allogeneic HSCT in case required. Therefore, the use of
alternative donors such as haploidentical or cord blood
transplants may increase somewhat due to urgent situations
when a patient’s primary diagnosis would not allow defer-
ring transplant for later.
Blood banks play a vital role to ensure the efficient
functioning of any transplant center. However, the current
COVID-19 pandemic has decreased the nationwide volun-
teer blood donations. Blood product shortage needs to be
anticipated before and an effective communication with
the other local blood banks as a source of blood products
should be in place [2]. These blood shortages are probably
the result of nonpharmacological interventions such as
home sheltering, social distancing, home quarantine, etc.
which are being promoted in order to suppress the com-
munity transmission of SARS-CoV-2 spread [3]. Unfortu-
nately, this has led to an unprecedented cancellation of
blood donation drives. This adds an additional responsi-
bility on the transplant team to keep coordinating with the
blood bank colleagues to ensure blood products are avail-
able 24 × 7. Pagano et al. in their report discussed the
measures taken to defend blood shortage at the University
of Washington, Seattle. Based on their observation, steps
such as canceling the elective surgeries and procedures,
requesting one unit of red blood cells at a time, rechecking
on the indications of blood product order requests, and
calling for more blood donation drives could help the blood
centers and hospitals to tide over the COVID-19 crisis
(https://fda.gov/news-events/press-announcements/corona
virus-covid-19-update-blood-donations) [4]. To spare
the scarce resources (regular and ICU beds, personnel,
blood products, etc.) that are expected to be in high demand
during the COVID-19 surge, transplant centers have
been postponing stem cell transplants whenever clinically
possible [5].
In conclusion, given the limited experience with the
SARS-CoV-2 virus, we anticipate more modifications in the
interim recommendations. As COVID-19 is an evolving
disease, for decision-making, paying attention to reports
from local health authorities, reviewing the latest data, and
following interim guidelines is essential to ensure uni-
formity in the approach to transplant patients.
Author contributions All authors have seen the manuscript and agree
to the content and data. All the authors played a significant role in
the paper.
Compliance with ethical standards
Conflict of interest The authors declare that they have no conflict of
interest.
Ethics statement The article does not contain the participation of any
human being and animal.
Publisher’s note Springer Nature remains neutral with regard to
jurisdictional claims in published maps and institutional affiliations.
References
1. Sahu KK, Mishra AK, Lal A. Novel coronavirus (2019-nCoV):
update on 3rd coronavirus outbreak of 21st century. QJM. 2020.Mar
3. pii: hcaa081.
2. Ueda M, Martins R, Hendrie PC, McDonnell T, Crews JR, Wong
TL, et al. Managing cancer care during the COVID-19 pandemic:
agility and collaboration toward a common goal. J Natl Compr
Cancer Netw. 2020;20:1–4.
3. Sahu KK, Lal A, Mishra AK. Latest updates on COVID-2019: a
changing paradigm shift. J Med Virol. 2020. Mar 20.
4. Pagano MB, Hess JR, Tsang HC, Staley E, Gernsheimer T, Sen N,
et al. Prepare to adapt: blood supply and transfusion support during
the first 2 weeks of the 2019 Novel Coronavirus (COVID-19)
pandemic affecting Washington State. Transfusion. 2020 Mar 21.
5. Sahu KK, Jindal V, Siddiqui AD. Managing COVID-19 in Patients
With Cancer: A Double Blow for Oncologists. JCO Oncol Pract.
2020 Apr 17:OP2000167.
COVID-19 pandemic and impact on hematopoietic stem cell transplantation
